AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor HoldingsSeeking Alpha • 12/15/25
Ultragenyx (RARE) Up 14.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference TranscriptSeeking Alpha • 12/03/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Citi Annual Global Healthcare Conference 2025 TranscriptSeeking Alpha • 12/03/25
Here's What Key Metrics Tell Us About Ultragenyx (RARE) Q3 EarningsZacks Investment Research • 11/04/25
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life SciencesGlobeNewsWire • 11/04/25
Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 10/28/25
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should KnowZacks Investment Research • 10/28/25
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice PresidentGlobeNewsWire • 09/30/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/23/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
RARE Reports Positive Long-Term Data From Metabolic Disorder StudyZacks Investment Research • 09/09/25
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 09/08/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewsWire • 08/29/25
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 08/18/25
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 08/05/25
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 07/30/25